ClinicalTrials.Veeva

Menu
R

Retina Center of Texas | Southlake, TX

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Faricimab
UBX1325
IONIS-FB-LRx
THR-687
AU-011
Zimura
Ranibizumab
Avacincaptad pegol
Foselutoclax

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 13 total trials

A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm (PAVILION)

Study GR41675 is a Multicenter, Randomized Study in Participants with Diabetic Retinopathy (DR) Without Center-Involved Diabetic Macular Edema (CI-DM...

Active, not recruiting
Diabetic Retinopathy
Drug: Intravitreal Ranibizumab 0.5 mg Injection
Drug: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab

The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary i...

Enrolling
Indeterminate Lesions
Ocular Melanoma
Device: Suprachoroidal Microinjector
Drug: Sham Treatment

This main long-term extension study is designed to evaluate the long-term safety and tolerability of faricimab 6 milligrams (mg) administered by intr...

Active, not recruiting
Neovascular Age-related Macular Degeneration
Other: Sham Procedure
Drug: Faricimab

This study is designed to investigate treatment response in treatment-naïve underrepresented patients with diabetic macular edema (DME) who are treat...

Enrolling
Diabetic Macular Edema
Drug: Faricimab

The goal of this clinical trial is to assess the efficacy and safety of multiple doses of foselutoclax (UBX1325) in patients with Diabetic Macular Ed...

Enrolling
Edema
Diabetic Macular Edema
Drug: foselutoclax
Drug: Aflibercept

The purpose of this study is to assess long-term safety of avacincaptad pegol intravitreal administration for patients with geographic atrophy (GA) w...

Active, not recruiting
Age-Related Macular Degeneration
Geographic Atrophy
Drug: avacincaptad pegol

Trial sponsors

Roche logo
U
Astellas logo
Aura Biosciences logo
Genentech logo
Ionis Pharmaceuticals logo
I
Oxurion logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems